TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05142436

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product A: Non-Combusted Cigarette Variant 42001402 and product use Mode B
Description: 42001402, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode B

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product B: Non-Combusted Cigarette Variant 42001399 and product use Mode B
Description: 42001399, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode B

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product C: Non-Combusted Cigarette Variant 42001401 and product use Mode B
Description: 42001401, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode B

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product D: Non-Combusted Cigarette Variant 40007386 and product use Mode B
Description: 40007386, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode B

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Product E: Non-Combusted Cigarette Variant 42001402 and product use Mode A
Description: 42001402, A Heated Tobacco Product using a Non-Combusted Cigarette Variant and product use Mode A
Study: NCT06484023

Intervention type: OTHER
Intervention: Survey
Description: quality of life questionnaire
Study: NCT06066060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMKX000623
Description: JMKX000623, administered orally ;
Study: NCT04706975

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: difelikefalin 2.0 mg
Description: Oral difelikefalin 2.0 mg administered twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Placebo administered twice daily
Study: NCT06066060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin,administered orally
Study: NCT04284969

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROADAPT program
Description: * A pre-intervention activity by telephone follow-ups every week for 12 weeks and then every month.~* Pre-operative physical training including strength, endurance and breathing exercises.~* A nutrition activity.~* An activity to educate patients (on nutrition, exercise).~* The implementation of standardised intervention procedures, established in agreement with the surgeons' representatives.~* A pharmaceutical drug conciliation activity: optimization of the patient's different treatments with pharmaceutical expertise.~* A transition activity from the hospital to the home, and a telephone follow-up up to 12 weeks after the surgery.
Study: NCT04862793

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colonoscopy Progression Score (CoPS)
Description: The Colonoscopy Progression Score consists of five different aspects: Travel length, Tip progression, chase efficiency, shaft movement without tip progression and looping.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colonoscopy Retraction Score (CoRS)
Description: The Colonoscopy Retraction Score consists of three different aspects: Tip Retraction, Retraction Efficiency, and Retraction Distance.
Study: NCT05332522

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuroplasticity-based Computerized Cognitive Remediation
Description: The nCCR has two major components: Bottom up and Top down training.~Bottom up training: The training includes selected tasks from Brain HQ, a program designed for older adults, that enhances basic processing of sensory stimuli with the goal to improve fidelity of auditory and visual encoding.~Top down training: We designed programs to target cognitive control functions associated with poor treatment response, i.e., initiation and use of verbal strategy and susceptibility to interference. These Top Down Programs include a visual attention program, either Catch the Ball or Neurogrow, and a semantic strategy program, Semantic Organization.
Study: NCT05022927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERY974
Description: ERY974 vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERY974
Description: ERY974 vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERY974
Description: ERY974 vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERY974
Description: ERY974 vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERY974
Description: ERY974 vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilicumab
Description: Tocilizumab vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilicumab
Description: Tocilizumab vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilicumab
Description: Tocilizumab vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilicumab
Description: Tocilizumab vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilicumab
Description: Tocilizumab vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab vial

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab vial
Study: NCT04998032

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: supaglutide injection+metformin
Description: supaglutide subcutaneous injection under RP3D dose combined with metformin treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo+metformin
Description: placebo subcutaneous injection combined with metformin treatment
Study: NCT05889221

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug and medical device
Description: Isatuximab will be administered in the hospital by an healthcare professional in the periumbilical region at a single site, using an investigational device injector; injection site will be rotated from one administration to the other.
Study: NCT06543407

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SWITCH IT
Description: Behavioral support for switching, 7-10 sessions with SWITCH IT coach delivered during the first 8 weeks of the study. SWITCH IT participants will also have the opportunity to receive supported field trips to explore e-cigarette options based on availability, cost, and preferences during week 4 and week 6.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: E-cig Provision Only
Description: Provision of e-cigarettes (NJOY) based on combusible use for the first 8 weeks of the study.
Study: NCT06320535

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21/Matrix M™ (Group 1)
Description: * 0.50 mcg R21 in 2.75 mcg Matrix-M™ (D0)~* 0.75 mcg R21 in 3.5 mcg Matrix-M™ (D3)~* 1.25 mcg R21 in 6.25 mcg Matrix-M™ (D7)~* 2.5 mcg R21 in 12.5 mcg Matrix-M™ (D10)~* 5 mcg R21 in 25 mcg Matrix-M™ (D14)~* 10 mcg R21 in 50 mcg Matrix-M™ (D56)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21/Matrix M™ (Group 2)
Description: * 0.50 mcg R21 in 2.75 mcg Matrix-M™ (D0)~* 0.75 mcg R21 in 3.5 mcg Matrix-M™ (D3)~* 1.25 mcg R21 in 6.25 mcg Matrix-M™ (D7)~* 2.5 mcg R21 in 12.5 mcg Matrix-M™ (D10)~* 5 mcg R21 in 25 mcg Matrix-M™ (D14)~* 10 mcg R21 in 50 mcg Matrix-M™(D168)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: R21/Matrix M™ (Group 3)
Description: * 10 mcg R21 in 50 mcg Matrix-M™ (D0)~* 10 mcg R21 in 50 mcg Matrix-M™ (D56)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fine needle aspiration (FNA)
Description: Participants in all groups will undergo fine needle aspiration (FNA) of axillary lymph nodes draining vaccination site on Day 77 and Day 105 after initial vaccination.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fine needle aspiration (FNA)
Description: Participants in all groups will undergo fine needle aspiration (FNA) of axillary lymph nodes draining vaccination site on Day 77 and Day 105 after initial vaccination.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fine needle aspiration (FNA)
Description: Participants in all groups will undergo fine needle aspiration (FNA) of axillary lymph nodes draining vaccination site on Day 77 and Day 105 after initial vaccination.
Study: NCT05288504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVTX-002
Description: Dose of 600 mg administered subcutaneously three times during the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sourced as normal saline administered subcutaneously three times during the study.
Study: NCT05605899

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Axicabtagene Ciloleucel
Description: A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Administered orally
Study: NCT05837624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estetrol/Drospirenone
Description: 6-month course of oral estetrol/drospirenone (15 mg estetrol monohydrate / 3 mg drospirenone) once daily for the study duration
Study: NCT06006780

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Porcine acellular dermal matrix
Description: Coronally advanced flap associated with the porcine acellular dermal matrix for root coverage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coronally advanced flap (CAF)
Description: Coronally advanced flap for root coverage
Study: NCT05879991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1810631 (C-14) formulation 1
Description: BI 1810631 (C-14) formulation 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1810631
Description: BI 1810631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1810631 (C-14) formulation 2
Description: BI 1810631 (C-14) formulation 2
Study: NCT05813132

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BEAM Protocol
Description: BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CEM protocol
Description: CEM (Carboplatin, Etoposide, Melphalan)
Study: NCT06084260

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Diet group
Description: Individual diet, with caloric restriction, associated with weekly meetings about eating habits modifications.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-compassion group
Description: Weekly meetings using self-compassion techniques to improve body dissatisfaction and eating behavior.
Study: NCT06269900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone phosphate injection is given as a slow injection or infusion (intravenous drip) into the veins.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo injection is given as a slow injection or infusion (intravenous drip) into the veins.
Study: NCT05835037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc Gluconate 30 MG
Description: Participants will take one tablet per day (30 mg Zinc gluconate) for 1 year

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take one placebo tablet per day for 1 year
Study: NCT04858269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg intravenously (IV) on day 1 of each 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin dosed for area under the curve (AUC) 1.5 IV on days 1, 8, 15 of each 3-week cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 45 mg/m2 on days 1, 8, 15 of 3-week cycle.
Study: NCT05110859

Intervention type: OTHER
Intervention: in-depth individual interviews
Description: in-depth individual interviews to explore their perspectives on their first work experience during covid-19 pandemic
Study: NCT05638867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin + Clopidogrel + Rivaroxaban
Description: Triple antithrombotic therapy: aspirin 75-100 mg orally once daily, clopidogrel 75 mg orally once daily, and rivaroxaban 2.5 mg orally twice daily

Intervention type: DRUG
Group type: OTHER
Intervention: Aspirin + Clopidogrel
Description: Dual antithrombotic therapy: aspirin 75-100 mg orally once daily, clopidogrel 75 mg orally once daily
Study: NCT04732962

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AposHealth
Description: AposHealth is comprised of a unique footwear (Apos device) and uses two convex pods called Pertupods, which are screwed into the plantar surface of the sole so that a person walks on these pods. A trained Apos therapist calibrates the devices. The location of the pods is adjusted according to the treatment methodology, depending on the needed effect on unloading the knee and with the purpose of potentially alleviating pain immediately.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AposHealth
Description: AposHealth is comprised of a unique footwear (Apos device) and uses two convex pods called Pertupods, which are screwed into the plantar surface of the sole so that a person walks on these pods. A trained Apos therapist calibrates the devices. The location of the pods is adjusted according to the treatment methodology, depending on the needed effect on unloading the knee and with the purpose of potentially alleviating pain immediately.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Knee Replacement (TKR)
Description: A total knee replacement occurs when a diseased or damaged knee joint is totally replaced with an artificial joint called an implant. The implant consists of high-grade metal and plastic components that fuse to the resurfaced bone. It is designed to move like a healthy human joint.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Knee Replacement (TKR)
Description: A total knee replacement occurs when a diseased or damaged knee joint is totally replaced with an artificial joint called an implant. The implant consists of high-grade metal and plastic components that fuse to the resurfaced bone. It is designed to move like a healthy human joint.
Study: NCT04547595

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hypnosis
Description: given by Expert in this method
Study: NCT06054776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT or CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glofitamab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT05258825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monoferric
Description: A single intravenous dose of 1000 mg of Monoferric will be administered to a patient 3-4 weeks before anticipated surgery.
Study: NCT05686057

Intervention type: DEVICE
Intervention: percutanous coronary angiography with stenting
Description: Revascularization will be done by percutanous intervention after assessment of coronary stenosis by diagnostic coronary angiography under local anaesthesia with fluoroscopic guidance in acute/chronic coronary syndrome cases. The severity of stenosis will be done by modified gensini score from angiogram. An sST2 ELIZA test will be done after withdrawal of the cases' samples.

Intervention type: DEVICE
Intervention: percutanous coronary angiography with stenting
Description: Revascularization will be done by percutanous intervention after assessment of coronary stenosis by diagnostic coronary angiography under local anaesthesia with fluoroscopic guidance in acute/chronic coronary syndrome cases. The severity of stenosis will be done by modified gensini score from angiogram. An sST2 ELIZA test will be done after withdrawal of the cases' samples.

Intervention type: DEVICE
Intervention: percutanous coronary angiography with stenting
Description: Revascularization will be done by percutanous intervention after assessment of coronary stenosis by diagnostic coronary angiography under local anaesthesia with fluoroscopic guidance in acute/chronic coronary syndrome cases. The severity of stenosis will be done by modified gensini score from angiogram. An sST2 ELIZA test will be done after withdrawal of the cases' samples.
Study: NCT05816239

Intervention type: PROCEDURE
Intervention: Dual Energy CT
Description: Patient will receive Dual Energy CT
Study: NCT05105295

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated COVID-19 vaccine
Description: receive a third dose of inactivated COVID-19 vaccine
Study: NCT05576792

Intervention type: OTHER
Intervention: Ranibizumab
Description: Prospective observational study. There is no treatment allocation. Patients prescribed with ranibizumab 0.2 mg in the commercial setting are eligible to enroll into this study.
Study: NCT06167187

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bilateral inferior alveolar nerve block
Description: Placing the tip of the thumb or forefinger into the coronoid notch (retromolar fossa) to help visualize the vertical height at which the needle will enter, and retracting the cheek to expose the pterygomandibular triangle. Placing the barrel of the syringe over the contralateral lower 1st and 2nd premolars and resting the side of the needle tip against the lateral edge of the pterygomandibular raphe, aiming the tip of the needle into the pterygomandibular triangle, with the bevel facing the ramus. Advancing the needle tip slightly into the mucosa until it is stopped by the ramus (typically after about 2 to 2.5 cm of insertion) and withdrawing needle 1 mm away from bone. Aspirating to rule out intravascular placement. If aspiration reveals intravascular placement, withdrawal of the needle will be done 2 to 3 mm, then reaspirating prior to injection. Slowly injecting about 2 to 4 milliliters of bupivacaine 0.5% anesthetic in each side..

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac and fentanyl
Description: in control group, Patients will not receive the block and pain will be controlled according to institutional protocol using 30 mg ketorolac IV and fentanyl increments as needed.
Study: NCT05973526

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Electrolipolysis
Description: Electrolipolysis consists in the passage of electric current to the adipose tissue, causing lipolysis. The proposed protocol consists of 2 weekly sessions for 6 weeks, totaling 12 sessions, using needles.
Study: NCT06468345

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: acupressure
Description: Application was made to CV12, ST25, SP6, HT7 and LI4 acupressure areas.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Area different from acupressure area
Description: Massage application to non-acupressure hand, foot and abdominal areas
Study: NCT05973526

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrolipolysis
Description: Electrolipolysis consists in the passage of electric current to the adipose tissue, causing lipolysis. The proposed protocol consists of 2 weekly sessions for 6 weeks, totaling 12 sessions, using the surface electrodos.
Study: NCT05314127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% Gel,Top
Description: once daily topical application at night with a cotton tipped applicator on every lesion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imiquimod
Description: Imiquimod cream 5% applied once daily at night with a cotton tipped applicator applied once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil Cream
Description: 5- Fluorouracil Cream 5% is applied once daily at night with a cotton tipped applicator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Petrolatum
Description: applied once daily at night
Study: NCT05094869

Intervention type: BEHAVIORAL
Intervention: Use of mobile health application
Description: The APP would regularly send messages including the medication reminder, health education knowledge, etc.

Intervention type: BEHAVIORAL
Intervention: Use of mobile health application
Description: The APP would regularly send messages including the medication reminder, health education knowledge, etc.

Intervention type: BEHAVIORAL
Intervention: Online interaction
Description: The patients would be able to upload their examination results in the APP and then the doctors will evaluate their disease progression every six months through the APP and guide patients' clinical practice accordingly.

Intervention type: BEHAVIORAL
Intervention: Self follow-up reminders
Description: The APP would regularly send messages including the follow-up reminder (manually set up by the patient on the APP)

Intervention type: BEHAVIORAL
Intervention: Intelligent follow-up reminders
Description: The APP would regularly send messages including the follow-up reminder (automatically set up by the APP)
Study: NCT05000671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STC314 injection or Placebo(rate=58.3 mg/hr)
Description: To receive continuous infusion of STC314/Placebo injection at rate 58.3mg/hr up to 3 days (72hours). Also to receive appropriate standard of care.